Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial.
Lassen MCH, Ostrominski JW, Inzucchi SE, Claggett BL, Kulac I, Jhund P, de Boer RA, Hernandez AF, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Desai AS, Petersson M, Langkilde AM, Docherty KF, McMurray JJV, Solomon SD, Vaduganathan M.
Lassen MCH, et al. Among authors: hernandez af.
Eur J Heart Fail. 2024 May 15. doi: 10.1002/ejhf.3269. Online ahead of print.
Eur J Heart Fail. 2024.
PMID: 38745498